⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105432 | 1.00 | — | — | |
| SCHEMBL3854594 | 1.00 | OPRM1 (0.82) | — | |
| SCHEMBL353779 | 1.00 | — | — | |
| SCHEMBL28678588 | 0.97 | — | — | |
| Water SCHEMBL11207167 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3814517 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL5176935 | 0.97 | — | — | |
| Iodide SCHEMBL27231983 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL8347529 | 0.97 | — | — | |
| Bromide SCHEMBL27224648 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215047-A1 | MUTATED BACTERIAL STRAINS TOLERANT TO ELEVATED CONCENTRATIONS OF AMINES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2025-10-16 | — | — | WO | claimed |
| CN-112280761-B | Recombinant transaminase, mutant of recombinant transaminase and application of mutant | 清华大学 | 2022-04-12 | — | — | CN | claimed |
| CN-112280761-A | Recombinant transaminase, mutant of recombinant transaminase and application of mutant | 清华大学 | 2021-01-29 | — | — | CN | claimed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| EP-2069320-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | Teva Pharmaceutical Industries Ltd. (IL) | 2009-06-17 | — | — | EP | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| WO-2008151170-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-11 | — | — | WO | claimed |
| CN-116854630-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2025215047-A1 | MUTATED BACTERIAL STRAINS TOLERANT TO ELEVATED CONCENTRATIONS OF AMINES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240282401-A1 | METHODS FOR ENZYME ENGINEERING | THE UNIVERSITY OF MANCHESTER (GB) | 2024-08-22 | — | — | US | disclosed |
| CN-118440121-A | Ruthenium complex, synthesis method and application | 西湖大学 | 2024-08-06 | — | — | CN | disclosed |
| US-20070155671-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER | 2007-07-05 | — | — | US | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1171405-B1 | FUNCTIONALISED SOLID SUPPORT FOR ALPHA-OXOALDEHYDE SYNTHESIS | PASTEUR INSTITUT (FR) | 2007-01-03 | — | — | EP | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| WO-1999012912-A1 | THIOUREA DERIVATIVES OR NON-TOXIC SALTS THEREOF FOR INHIBITNG RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION (KR) | 1999-03-18 | — | — | WO | disclosed |